NCT04900363View on ClinicalTrials.gov

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

September 30, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

AK112

Subjects receive AK112 intravenously.

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY